

Peer Review File

Article information: <https://dx.doi.org/10.21037/tlcr-22-713>

Round 1

Reviewer Comments

1. Would remove Table 1 as this topic would have been covered in detail in other reviews of the series?

Reply 1: The authors prefer to leave Table 1 in place for readers who find this article using search engines, and read this article apart from remainder of this TLCR special issue.

2. Suggest removing Figure 4 as this reveals oncologists' contact info (address, phone number).

Reply 2: Figure 4 is revised by removal of oncologist's telephonic contact information. Institutional/postal address information that remains is a matter of public record.

3. Figure 6 - Would make sure these individuals provided consent for their photos to be shown in the manuscript - could remove given the number of figures in the review.

Reply 3: Figure 6 has been removed.

4. Table 2 could be removed - not necessary for the review (more important to provide general info re: history and structure).

Reply 4: We prefer to leave Table 2 – revised manuscript Table 3 – in the revised manuscript, to illustrate the types of research ALK Positive is supporting. The table has been updated to include 2022 awards.

5. Figures 13 and 14 could be combined into 1 figure or two panels in a figure.

Reply 5: The authors prefer to retain original Figs 13 and 14 – revised manuscript Figures 11 and 12 – separately, for the improved readability of the separate figures.

6. Figure 11 could be removed. Figure 2 could be removed.

Reply 6: Figure 11 has been removed. The authors would like to retain Fig 2, as we think it provides a relatable image for our organization and the figure legend includes the URL for ALK Positive.

Round 2

Reviewer Comments

1) Table 1- We had suggested to remove but was kept in. This table can actually be misleading the way it is presented with fusion partners, on-target ALK mutations, bypass resistance, and TKIs, listed side by side. It makes it seem like perhaps one TKI should be associated with one fusion partner or one ALK mutation, etc., when that is not true and it is also not the authors' intention either. This is also info that is covered in much more detail in other dedicated reviews of this series and has also been already covered in other published reviews. It should be removed.

Reply 1: Table 1 has been removed.

2) Table 2 - This was added. However, these are data straight from reference 15 without any additional analyses or adding meaningfully. It should be removed. The authors, I believe, meant to respond to one of the reviewer/editorial comments re: being more specific and summarizing the evidence for decreased PFS/OS with chemo vs ALK TKIs for pts with ALK+ lung cancer (rather than stating “much lower median PFS and lower median OS than...” as in lines 155-156 on pg 6). They should, rather than adding this table, revise the sentence itself to be more quantitative and less subjective (i.e., “with shorter median PFS and shorter median OS than... For example, per one Cochrane Database systematic review of randomized trials, HR for PFS with chemotherapy vs ALK-targeted therapies was 0.45, etc (cite ref 15)).

Reply 2: Table 2 has been removed. Text within Revision1 Tracked lines 112-115 has been altered as suggested, with citation of Reference 15.

3) Fig. 4 - Again, this is unnecessary. We had suggested to be removed in the initial review. I still believe this should be removed. The article can refer to the website for further details.

Reply 3: Figure 4 has been removed.

4) Table 3 - Had suggested to be removed; again, should be removed. This takes up a lot of space, and details can be found on the website.

Reply 4: Table 3 has been removed.

5) Fig. 11+12. - Had suggested to merge into one figure with 2 panels - again, would suggest doing so given the # of figures and given that these are both schema of two different committees within the group.

Reply 5: Figures 11+12 have been combined into Revision1 Figure 9.

6) Fig 7 - This does not add to the review and can be removed.

Reply 6: Figure 7 has been removed.

Round 3

Reviewer Comments

1. Line 97: delete “ALK overexpression or ALK-fusion partner genomic rearrangements” and instead write “ALK rearrangements”

Reply 1: Text has been so edited, and references modified.

2. Lines 103-105: please add reference

Reply 2: New References 17 and 18 have been added.

3. Lines 143-145: please add reference

Reply 3: New References 26 and 27 have been added.